Products for Research Use Only
RegisterLogin

Patritumab

CAT: 0804-HY-P99275-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99275-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab , potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].
CAS Number
1262787-83-6
Product Name Alternative
Human Anti-ERBB3 Recombinant Antibody
UNSPSC
12352203
Target
Akt; EGFR; ERK; PARP; Survivin
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/patritumab.html
Purity
99.28
Solubility
10 mM in DMSO
Smiles
[Patritumab]
Molecular Weight
(146.86 kDa)
References & Citations
[1]Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5 (23) :11847-56.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
M36726-01Patritumab
T9901A-198-01Patritumab MMAE
C00965-1mg*5Patritumab deruxtecan
592101Patritumab (ERBB3)
GTR18337987-01Patritumab Antibody
HB116046-01Research Grade Patritumab
MBS1581223-01Patritumab deruxtecan (ADC)
GTR18398557-01Patritumab deruxtecan Antibody
E55B0535Patritumab (Reference antibody)
GTR18578320-01Patritumab MMAE Antibody

Popular Products